Illumina Posts Higher 1Q Profit, Sales, Citing Growing Demand for NovaSeq X

Dow Jones

May 01

By Paul Ziobro

Illumina posted higher profit and sales in the first quarter, citing rising demand for its gene-sequencing machines.

The genomics company on Thursday reported a profit of $134 million, or 87 cents a share, compared with $131 million, or 82 cents, in the same quarter a year ago.

Adjusted earnings came in at $1.15 a share. Analysts polled by Factset expected $1.05 a share.

Revenue rose 4.8% to $1.09 billion, ahead of the $1.07 million expected by analysts.

Chief Executive Jacob Thaysen said that demand for its NovaSeq X machine is increasing as the company helps its clinical customers expand into new application areas.

With the strong start to the year, Illumina bumped up its guidance. It now expects revenue between $4.52 billion and $4.62 billion, up $20 million at the midpoint versus its prior guidance.

It now forecasts adjusted per-share earnings between $5.15 and $5.30, up from $5.05 to $5.20.

Write to Paul Ziobro at paul.ziobro@wsj.com

(END) Dow Jones Newswires

April 30, 2026 16:05 ET (20:05 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2632651206"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2632651206\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2632651206?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-01 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2632651206","market":"nz","top_or_hot":-1,"title":"Illumina Posts Higher 1Q Profit, Sales, Citing Growing Demand for NovaSeq X","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Paul Ziobro \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ILMN\">Illumina</a> posted higher profit and sales in the first quarter, citing rising demand for its gene-sequencing machines. \n</p>\n<p>\n  The genomics company on Thursday reported a profit of $134 million, or 87 cents a share, compared with $131 million, or 82 cents, in the same quarter a year ago. \n</p>\n<p>\n  Adjusted earnings came in at $1.15 a share. Analysts polled by Factset expected $1.05 a share. \n</p>\n<p>\n  Revenue rose 4.8% to $1.09 billion, ahead of the $1.07 million expected by analysts. \n</p>\n<p>\n  Chief Executive Jacob Thaysen said that demand for its NovaSeq X machine is increasing as the company helps its clinical customers expand into new application areas. \n</p>\n<p>\n  With the strong start to the year, Illumina bumped up its guidance. It now expects revenue between $4.52 billion and $4.62 billion, up $20 million at the midpoint versus its prior guidance. \n</p>\n<p>\n  It now forecasts adjusted per-share earnings between $5.15 and $5.30, up from $5.05 to $5.20. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 30, 2026 16:05 ET (20:05 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Illumina Posts Higher 1Q Profit, Sales, Citing Growing Demand for NovaSeq X</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIllumina Posts Higher 1Q Profit, Sales, Citing Growing Demand for NovaSeq X\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-01 04:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Paul Ziobro \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ILMN\">Illumina</a> posted higher profit and sales in the first quarter, citing rising demand for its gene-sequencing machines. \n</p>\n<p>\n  The genomics company on Thursday reported a profit of $134 million, or 87 cents a share, compared with $131 million, or 82 cents, in the same quarter a year ago. \n</p>\n<p>\n  Adjusted earnings came in at $1.15 a share. Analysts polled by Factset expected $1.05 a share. \n</p>\n<p>\n  Revenue rose 4.8% to $1.09 billion, ahead of the $1.07 million expected by analysts. \n</p>\n<p>\n  Chief Executive Jacob Thaysen said that demand for its NovaSeq X machine is increasing as the company helps its clinical customers expand into new application areas. \n</p>\n<p>\n  With the strong start to the year, Illumina bumped up its guidance. It now expects revenue between $4.52 billion and $4.62 billion, up $20 million at the midpoint versus its prior guidance. \n</p>\n<p>\n  It now forecasts adjusted per-share earnings between $5.15 and $5.30, up from $5.05 to $5.20. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 30, 2026 16:05 ET (20:05 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ILMN","symbol_name":"Illumina","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2632651206","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2632651206","pubTimestamp":1777579500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Illumina posted higher profit and sales in the first quarter, citing rising demand for its gene-sequencing machines.The genomics company on Thursday reported a profit of $134 million, or 87 cents a share, compared with $131 million, or 82 cents, in the same quarter a year ago.Adjusted earnings came in at $1.15 a share. Analysts polled by Factset expected $1.05 a share.Revenue rose 4.8% to $1.09 billion, ahead of the $1.07 million expected by analysts.Chief Executive Jacob Thaysen said that demand for its NovaSeq X machine is increasing as the company helps its clinical customers expand into new application areas.With the strong start to the year, Illumina bumped up its guidance. It now expects revenue between $4.52 billion and $4.62 billion, up $20 million at the midpoint versus its prior guidance.It now forecasts adjusted per-share earnings between $5.15 and $5.30, up from $5.05 to $5.20.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ILMN":"Illumina","SOCL":"社交媒体ETF-Global X"},"translate_title":"Illumina公布第一季度利润和销售额较高，原因是对NovaSeq X的需求不断增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SOCL":1.5,"ILMN":1.5},"content_text":"By Paul Ziobro \n\n\n \n\n\nIllumina posted higher profit and sales in the first quarter, citing rising demand for its gene-sequencing machines. \n\n\n  The genomics company on Thursday reported a profit of $134 million, or 87 cents a share, compared with $131 million, or 82 cents, in the same quarter a year ago. \n\n\n  Adjusted earnings came in at $1.15 a share. Analysts polled by Factset expected $1.05 a share. \n\n\n  Revenue rose 4.8% to $1.09 billion, ahead of the $1.07 million expected by analysts. \n\n\n  Chief Executive Jacob Thaysen said that demand for its NovaSeq X machine is increasing as the company helps its clinical customers expand into new application areas. \n\n\n  With the strong start to the year, Illumina bumped up its guidance. It now expects revenue between $4.52 billion and $4.62 billion, up $20 million at the midpoint versus its prior guidance. \n\n\n  It now forecasts adjusted per-share earnings between $5.15 and $5.30, up from $5.05 to $5.20. \n\n\n \n\n\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 30, 2026 16:05 ET (20:05 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}